Compare Lupin with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs GSK PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN GSK PHARMA LUPIN/
GSK PHARMA
 
P/E (TTM) x 46.3 52.8 87.7% View Chart
P/BV x 4.3 11.9 35.8% View Chart
Dividend Yield % 0.5 1.3 38.3%  

Financials

 LUPIN   GSK PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-20
GSK PHARMA
Mar-19
LUPIN/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs8823,595 24.5%   
Low Rs5051,253 40.3%   
Sales per share (Unadj.) Rs339.4184.7 183.8%  
Earnings per share (Unadj.) Rs-5.926.3 -22.6%  
Cash flow per share (Unadj.) Rs15.529.2 53.1%  
Dividends per share (Unadj.) Rs6.0020.00 30.0%  
Dividend yield (eoy) %0.90.8 104.8%  
Book value per share (Unadj.) Rs276.7126.3 219.1%  
Shares outstanding (eoy) m453.00169.40 267.4%   
Bonus / Rights / Conversions ESOP--  
Price / Sales ratio x2.013.1 15.6%   
Avg P/E ratio x-116.692.2 -126.5%  
P/CF ratio (eoy) x44.883.1 53.9%  
Price / Book Value ratio x2.519.2 13.1%  
Dividend payout %-100.976.1 -132.6%   
Avg Mkt Cap Rs m314,201410,626 76.5%   
No. of employees `00018.35.0 369.0%   
Total wages/salary Rs m29,8685,372 556.0%   
Avg. sales/employee Rs Th8,400.66,306.7 133.2%   
Avg. wages/employee Rs Th1,632.01,083.1 150.7%   
Avg. net profit/employee Rs Th-147.2898.0 -16.4%   
INCOME DATA
Net Sales Rs m153,74831,281 491.5%  
Other income Rs m4,8381,023 472.8%   
Total revenues Rs m158,58532,304 490.9%   
Gross profit Rs m24,8496,009 413.5%  
Depreciation Rs m9,702486 1,996.3%   
Interest Rs m3,6306 60,496.7%   
Profit before tax Rs m16,3556,540 250.1%   
Minority Interest Rs m40-   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,521287 -2,620.5%   
Tax Rs m11,5712,373 487.6%   
Profit after tax Rs m-2,6944,454 -60.5%  
Gross profit margin %16.219.2 84.1%  
Effective tax rate %70.836.3 195.0%   
Net profit margin %-1.814.2 -12.3%  
BALANCE SHEET DATA
Current assets Rs m154,13220,061 768.3%   
Current liabilities Rs m92,25214,543 634.3%   
Net working cap to sales %40.217.6 228.2%  
Current ratio x1.71.4 121.1%  
Inventory Days Days8257 144.6%  
Debtors Days Days12914 919.5%  
Net fixed assets Rs m89,08214,343 621.1%   
Share capital Rs m9061,694 53.5%   
"Free" reserves Rs m124,46119,704 631.6%   
Net worth Rs m125,36721,398 585.9%   
Long term debt Rs m17,9332 896,640.0%   
Total assets Rs m249,83939,113 638.8%  
Interest coverage x5.51,091.0 0.5%   
Debt to equity ratio x0.10 153,043.2%  
Sales to assets ratio x0.60.8 76.9%   
Return on assets %0.411.4 3.3%  
Return on equity %-2.120.8 -10.3%  
Return on capital %8.731.9 27.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,450534 9,634.8%   
Fx outflow Rs m19,4707,091 274.6%   
Net fx Rs m31,980-6,557 -487.7%   
CASH FLOW
From Operations Rs m14,6883,994 367.8%  
From Investments Rs m11,070-1,433 -772.3%  
From Financial Activity Rs m-8,906-3,584 248.5%  
Net Cashflow Rs m16,853-1,023 -1,647.0%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 50.7 0.4%  
Indian inst/Mut Fund % 11.3 10.2 110.8%  
FIIs % 31.9 23.8 134.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 15.4 65.6%  
Shareholders   98,259 102,036 96.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


May 14, 2021 (Close)

TRACK LUPIN

LUPIN - IPCA LABS COMPARISON

COMPARE LUPIN WITH

MARKET STATS